(Q40407903)

20 September 2017

Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas (English)

1 reference

20 September 2017

0 references

0 references

1 reference

2

1 reference

20 September 2017

Juan R Rodriguez-Madoz

series ordinal

1

1 reference

PubMed ID

15963931

20 September 2017

Cristian Smerdou

series ordinal

3

1 reference

20 September 2017

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

12

1 reference

20 September 2017

1

1 reference

20 September 2017

153-163

1 reference

Cytokines in cancer pathogenesis and cancer therapy

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Interleukin-12 in anti-tumor immunity and immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Interleukin-12 and the regulation of innate resistance and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Inhibition of angiogenesis in vivo by interleukin 12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Latest development in viral vectors for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

An overview of current delivery systems in cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Cancer therapy using a self-replicating RNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Systemic tumor targeting and killing by Sindbis viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Interferon-α and interleukin-12 gene therapy of cancer: interferon-α induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Cytokine gene transfer into dendritic cells for cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte respons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

Two-helper RNA system for production of recombinant Semliki forest virus particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.02.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2005.02.011

1 reference

20 September 2017

1 reference

PubMed ID

15963931